{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-24-000052","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.480537+00:00","generated_at":"2026-06-04T04:29:23.428887+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cartesian Therapeutics enters employment pacts with CSO Jewell ($420K) and CTO Kurtoglu ($440K)","bullets":["Christopher Jewell appointed CSO; annual base salary $420,000, target bonus 40%.","Metin Kurtoglu appointed CTO (was COO); annual base salary $440,000, target bonus 40%.","Severance: 12 months base pay, prorated bonus, and COBRA if terminated without cause or for good reason.","Change-in-control provision: accelerated vesting of time-based equity awards if termination occurs near a change.","Both executives subject to 12-18 month non-compete, non-solicit, and confidentiality covenants."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-24-000052","json":"https://secwatch.observer/filing/0001453687-24-000052.json","markdown":"https://secwatch.observer/filing/0001453687-24-000052.md","text":"https://secwatch.observer/filing/0001453687-24-000052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368724000052/0001453687-24-000052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368724000052/rnac-20240326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:29:23.428887+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0fe8bad26e","claim":"Christopher Jewell was appointed as Chief Scientific Officer at Cartesian Therapeutics, Inc..","evidence_excerpt":"As previously announced, on November 13, 2023, Cartesian Therapeutics, Inc. (the “Company”) appointed Christopher Jewell, Ph.D., age 43, to serve as the Company’s Chief Scientific Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368724000052/0001453687-24-000052-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"a25d1027a4","claim":"Metin Kurtoglu was appointed as Chief Technology Officer at Cartesian Therapeutics, Inc..","evidence_excerpt":"Under the terms of the Kurtoglu Employment Agreement, Dr. Kurtoglu will serve as the Company’s Chief Technology Officer, is entitled to receive an annual base salary of $440,000 and will be eligible for an annual performance bonus targeted at 40% of his annual base salary beginning in 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368724000052/0001453687-24-000052-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Technology Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}